Independent pharmacies occupy a critical role in community healthcare, providing prescription dispensing, medication therapy management, and increasingly specialty and compounding services that large chain pharmacies cannot easily replicate. The sector faces structural headwinds from PBM reimbursement compression and DIR fees, but independent operators with niche services, loyal patient bases, and long-term care contracts continue to generate stable cash flows attractive to strategic buyers. Consolidation is accelerating as retiring pharmacist-owners seek exits and PE-backed platforms pursue roll-up strategies in specialty and compounding niches.
Who buys these: Independent pharmacy operators, regional pharmacy chains, private equity-backed healthcare platforms, pharmacists seeking ownership, and strategic acquirers looking to expand geographic footprint or add specialty services
3–5.5×
Typical EBITDA multiple
$1M–$5M
Revenue range
Stable
Market trend
SBA Eligible
7(a) financing available
Recession Resistant
Essential service
Browse Pharmacy Businesses for Sale →
Search live acquisition targets near you — pre-filtered to Pharmacy
Buyers typically seek pharmacies with $1M–$5M in revenue, positive EBITDA margins of 8–15%, established customer/patient base with recurring prescription volume, clean DEA and state board compliance history, and ideally a mix of retail and specialty/compounding revenue to buffer PBM reimbursement risk
Get Deal Flow In Your Inbox
New Pharmacy acquisition targets delivered weekly — free to join.
Key items to investigate when evaluating a Pharmacy acquisition
What buyers typically pay for Pharmacy businesses
3×
Low Multiple
4.3×
Mid Multiple
5.5×
High Multiple
Pharmacy businesses in the $1M–$5M revenue range trade at 3–5.5× EBITDA in the lower middle market. Multiple variance is driven by recurring revenue percentage, owner dependency, client concentration, and growth trajectory. Stable demand allows consistent pricing near the midpoint for quality businesses.
Full valuation guide for PharmacyPharmacy acquisitions are SBA 7(a) eligible, meaning buyers can finance up to 90% of the purchase price. This expands the qualified buyer pool significantly and allows first-time acquirers to close with 10% down. Typical SBA terms run 10 years at prime + 2.75%. Sellers are often asked to carry a 5–10% note alongside SBA financing to satisfy the lender's equity requirement.
Typical acquirer profile for this segment
A licensed pharmacist seeking their first ownership opportunity using SBA financing, an existing independent pharmacy operator expanding their footprint, or a private equity-backed healthcare services platform pursuing a roll-up strategy in specialty or compounding pharmacy
What to investigate before buying a Pharmacy business
Seller Intelligence
Who sells Pharmacy businesses?
Independent pharmacy owners aged 55–70 approaching retirement, single-location pharmacists facing PBM reimbursement pressure, pharmacy founders looking to exit after building a loyal patient base, and owners of niche pharmacies such as compounding, long-term care, or specialty pharmacies
Typical exit timeline: 12–24 months
Pharmacy businesses in the $1M–$5M revenue range typically sell for 3–5.5× EBITDA. Buyers typically seek pharmacies with $1M–$5M in revenue, positive EBITDA margins of 8–15%, established customer/patient base with recurring prescription volume, clean DEA and state board compliance history, and ideally a mix of retail and specialty/compounding revenue to buffer PBM reimbursement risk
Pharmacy businesses typically trade at 3–5.5× EBITDA in the lower middle market. The market is moderately fragmented with stable demand, which puts pressure on pricing.
Pharmacy businesses are SBA 7(a) eligible, making them accessible to first-time buyers. Asset purchase with prescription file transfer and inventory priced separately at cost
Key due diligence areas include: PBM contract terms, reimbursement rates, and DIR fee exposure; Prescription file value, active patient count, and 30-day refill rate trends; DEA registration, state pharmacy board license transferability, and compliance history; Staff pharmacist and technician retention risk and licensing status; Inventory valuation methodology and accounts receivable aging from third-party payers.
More Pharmacy Guides
How to Buy a Pharmacy: The Complete Acquisition Guide
Independent pharmacies trade at 3–6x EBITDA with strong prescription revenue and motivated aging-owner sellers. Here's how to evaluate, finance, and close a pharmacy acquisition.
Independent vs. Chain Pharmacy Valuation: 2026 Guide
How independent and chain pharmacy valuations differ in 2026: script count benchmarks, DIR fee impact, 340B program, front-end revenue mix, and what buyers pay for each.
Pharmacy Acquisition Multiples in 2026: EBITDA & Revenue
2026 pharmacy acquisition multiples: 0.5x–1.5x revenue or 3x–6x EBITDA, PBM risk, script count benchmarks, DEA transfer, 340B eligibility, and what drives premium pricing.
Related Searches
DealFlow OS surfaces acquisition targets, scores seller motivation, and generates outreach — all in one place.
Start finding deals — freeNo credit card required
For Buyers
For Sellers